Status:

COMPLETED

Medacta NextAR TKA Pivotal Trial

Lead Sponsor:

Medacta International SA

Conditions:

Musculoskeletal Diseases

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this study is to assess the efficacy and safety of a navigation system providing personalized soft tissue balance data in medially-stabilized total knee arthroplasty (TKA).

Detailed Description

This is a prospective, multicentre, single-arm, open, confirmatory clinical investigation to assess the efficacy and safety of a navigation system providing personalized soft tissue balance data in me...

Eligibility Criteria

Inclusion

  • Males and females aged over 18 years at time of surgery.
  • Patients who are scheduled to receive Medacta GMK® Sphere system for primary TKA (class III, CE-marked).
  • Patients with functional contralateral knee (i.e. without the need to use walking aids).
  • Patients willing and able to provide written informed consent for participation.
  • Patients willing to comply with the pre and post-operative evaluation schedule.

Exclusion

  • Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study:
  • Patients presenting with progressive local or systemic infection
  • Muscular loss, neuromuscular disease or vascular deficiency of the affected limb, making the operation unjustifiable.
  • Severe instability secondary to advanced destruction of condralar structures or loss of integrity of the medial or lateral ligament
  • Patients whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems.
  • Patients affected by concomitant spine, hip, ankle or contralateral knee pathologies that can affect walking capacity.
  • Patients unable to understand and take action.
  • Patients with known allergy to the materials used.
  • Patients in which Medacta GMK® Sphere system is used in emergency interventions.

Key Trial Info

Start Date :

May 17 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 18 2024

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04844879

Start Date

May 17 2021

End Date

June 18 2024

Last Update

October 14 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Privatklinik Belair

Schaffhausen, Switzerland, 8200

2

Privatklinik Lindberg

Winterthur, Switzerland, 8400

3

Kantonsspital Winterthur

Winterthur, Switzerland, 8401

4

Uniklinik Balgrist

Zurich, Switzerland, 8008